Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

Figures & data

Table 1 Strategies for Preservation of Fertility and/or Ovarian Function in Women with Breast Cancer Diagnosed During Their Reproductive Years

	Time Needed Before Systemic Treatments	Recommended Age	Birth Rate	Contraindications
Oocyte/embryo cryopreservation^Citation30,Citation31	> 14 days	Preferably ≤ 40 years	43–62%*^Citation32	Coagulation deficits; high risk of infection; non-compliance with the required treatments and monitoring; urgent need to start anticancer therapies
Ovarian tissue cryopreservation^Citation33	2–3 days	Preferably ≤ 36 years	About 40%^Citation34,Citation35	High surgical or anesthesiologic risks; high risk of ovarian malignant contamination
Medical gonadoprotection^Citation36	~ 7 days	Premenopausal, any age	**	Non-compliance with the treatment

Notes: *Birth rates of oocyte/embryo cryopreservation vary according to the patient’s age and the number of oocytes collected. **This strategy has been studied as a technique to preserve ovarian function and not as a method for fertility preservation; nevertheless, an increased chance of pregnancy has been described.

Figure 1 The most important factors affecting the gonadotoxicity risk in women with breast cancer patients receiving chemotherapy.

Abbreviations: AMH, anti-Mullerian hormone; GnRHa, gonadotropin-releasing hormone analog.

OktayK, TuranV, BedoschiG, PachecoFS, MoyF. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol off J Am Soc Clin Oncol. 2015;33(22):2424–2429. doi:10.1200/JCO.2014.59.3723

 PubMed Web of Science ®Google Scholar

Diaz-GarciaC, DomingoJ, Garcia-VelascoJA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478–485.e2. doi:10.1016/j.fertnstert.2017.11.01829428307

 PubMed Web of Science ®Google Scholar

CoboA, García-VelascoJ, DomingoJ, PellicerA, RemohíJ. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–2231. doi:10.1093/humrep/dey32130383235

 PubMed Web of Science ®Google Scholar

GellertSE, PorsSE, KristensenSG, Bay-BjørnAM, ErnstE, Yding AndersenC. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35(4):561–570. doi:10.1007/s10815-018-1144-229497953

 PubMed Web of Science ®Google Scholar

MeirowD, Ra’ananiH, ShapiraM, et al. Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril. 2016;106(2):467–474. doi:10.1016/j.fertnstert.2016.04.03127181924

 PubMed Web of Science ®Google Scholar

PachecoF, OktayK. Current Success and Efficiency of Autologous Ovarian Transplantation: a Meta-Analysis. Reprod Sci Thousand Oaks Calif. 2017;24(8):1111–1120. doi:10.1177/1933719117702251

 PubMed Web of Science ®Google Scholar

LambertiniM, MooreHCF, LeonardRCF, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: a Systematic Review and Meta-Analysis of Individual Patient–Level Data. J Clin Oncol. 2018;36(19):1981–1990. doi:10.1200/JCO.2018.78.085829718793

 PubMed Web of Science ®Google Scholar